KLK3 and posterior cortical atrophy: Median time to treatment failure for enzalutamide-treated CR-PCa patients was also significantly shorter for ARV7-high and PSA-positive patients compared to ARV7-low and PSA-positive and PSA-negative patients (2.8 vs. 3.0 and 13.4 months, respectively) [87].